{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-000695","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.963694+00:00","generated_at":"2026-06-20T17:39:37.909564+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"KemPharm appoints Richard Pascoe as CEO; Travis Mickle resigns as CEO and President","bullets":["Richard W. Pascoe appointed CEO effective Jan 6, 2023; steps down as Executive Chairman.","Travis C. Mickle resigns as CEO (immediate) and as President and board member (at 2023 annual meeting).","Pascoe's base salary increased to $592,000, target bonus 55%, granted option for 700,000 shares.","Mickle receives severance (18 months base salary, COBRA, pro-rata bonus), accelerated option vesting, and consulting agreement ($40k/month + 547,945 performance RSUs).","Matthew R. Plooster appointed Chairman of the Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-000695","json":"https://secwatch.observer/filing/0001437749-23-000695.json","markdown":"https://secwatch.observer/filing/0001437749-23-000695.md","text":"https://secwatch.observer/filing/0001437749-23-000695.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923000695/0001437749-23-000695-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923000695/kmph20230108_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:39:37.909564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"206943a5dc","claim":"Matthew R. Plooster was appointed as Chairman of the Board at ZEVRA THERAPEUTICS, INC..","evidence_excerpt":"Additionally, the Board has appointed Matthew R. Plooster, a member of the Board, as the Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923000695/0001437749-23-000695-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"3f7c420c36","claim":"Richard W. Pascoe was appointed as Chief Executive Officer at ZEVRA THERAPEUTICS, INC..","evidence_excerpt":"On January 6, 2023, the Board of Directors (the “Board”) of KemPharm, Inc. (the “Company”) appointed Richard W. Pascoe to serve as the Company’s Chief Executive Officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923000695/0001437749-23-000695-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"447a05fe25","claim":"Travis C. Mickle resigned as Chief Executive Officer at ZEVRA THERAPEUTICS, INC..","evidence_excerpt":"On January 6, 2023, Dr. Mickle resigned his role (i) as Chief Executive Officer, effective immediately, and (ii) as President and as a member of the Board, in each case, effective as of the date of the Company’s 2023 Annual Meeting of Stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923000695/0001437749-23-000695-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}